HBOT for Mold Toxicity and CIRS: What the Evidence Actually Shows

If you have been told that mold made you sick and that hyperbaric oxygen therapy (HBOT) can "detox" your body and reverse it, you are right to want a straight answer. The honest one is uncomfortable: as of 2026, the direct evidence that HBOT treats mold toxicity or chronic inflammatory response syndrome (CIRS) is one single-patient case report, and the underlying diagnosis of "mold toxicity" is itself rejected by mainstream toxicology bodies. This article walks through what is actually published, what the proposed mechanism is, and how to think about HBOT here without getting taken advantage of.

What "Mold Toxicity" and CIRS Actually Mean

Before judging a treatment, you have to be clear about the condition it claims to treat. Two different ideas get blended together in marketing, and they are not the same.

"Mold allergy" is real and well accepted. Some people inhale mold spores and react with sneezing, congestion, asthma flares, or itchy eyes. Allergists test for it, and it responds to standard allergy care. Nobody serious disputes this.

"Mold toxicity" is a different and far more contested claim. The idea is that toxins made by mold (mycotoxins) in a water-damaged building get into your body and cause whole-body illness: brain fog, crushing fatigue, joint pain, mood changes, light sensitivity, and dozens of other symptoms. CIRS is the most structured version of this theory. It was developed by physician Ritchie Shoemaker, who proposed that genetically susceptible people cannot clear biotoxins, so they stay locked in chronic inflammation that hits many organ systems at once.

The CIRS framework comes with its own diagnostic toolkit: visual contrast sensitivity (VCS) eye testing, and a panel of blood markers like C4a, C3a, TGF-β1, MMP-9, and MSH. Proponents use these to "prove" the illness and track recovery. Critics point out that these same markers move around in lots of unrelated conditions and have never been validated as a specific test for one disease across independent labs.

This matters for HBOT because the case for treating CIRS with oxygen rests on a diagnosis that major medical organizations do not accept as a toxic illness in the first place.

It is worth being precise about the biomarkers, because they do a lot of persuasive work in mold clinics. C4a and C3a are complement-system fragments that rise during all kinds of inflammation, infection, and even after vigorous exercise. TGF-β1 is a signaling protein involved in tissue repair and immune regulation across countless conditions. MMP-9 is an enzyme that remodels tissue and climbs in wound healing, asthma, and cardiovascular disease. MSH is a hormone-like peptide. None of these is specific to mold. A panel of nonspecific markers, interpreted against proprietary reference ranges, can make almost any tired and inflamed person look like they "have CIRS." That is exactly the criticism mainstream reviewers raise: the markers are real lab values, but they do not point uniquely at one mold-caused disease.

Where the Mainstream Stands on Mold Illness

The split here is wide, and you deserve to know which side has the institutional weight.

The American College of Medical Toxicology (ACMT) issued updated guidance in 2025 stating plainly that "evidence does not support the idea that inhaled mycotoxins in home, school, or office environments cause significant toxic health effects." ACMT also cautions against unvalidated diagnostic tests (it singles out mycotoxin-antibody testing) and costly, unproven detoxification treatments, and concludes there is no diagnostic test or treatment supporting inhaled indoor mycotoxins as a cause of systemic toxicity. In ACMT's view, allergy — not toxicity — is the real mold-related health concern.

This builds on the National Academies' landmark 2004 report, "Damp Indoor Spaces and Health," which found consistent links between damp buildings and respiratory symptoms but did not establish that mycotoxin exposure causes the broad systemic illness now marketed as mold toxicity. The CDC likewise recommends fixing moisture problems and does not endorse biologic testing of people who live or work in water-damaged buildings.

None of this means people are imagining their symptoms. Damp, moldy environments clearly make some people feel terrible, through a mix of allergy, irritation, and inflammation. The dispute is about the specific story — circulating mycotoxins causing a distinct, testable, treatable toxic syndrome — and whether HBOT fixes it. That is the claim that lacks support.

The Mechanism: How HBOT Is Supposed to Help

HBOT works by having you breathe oxygen-enriched air inside a pressurized chamber. The higher pressure dissolves far more oxygen into your blood plasma than normal breathing does. In FDA-cleared uses like diabetic foot ulcers or carbon monoxide poisoning, that oxygen surge fights infection, helps grow new blood vessels, and rescues oxygen-starved tissue.

The proposed rationale for mold illness is different. The argument is that CIRS is fundamentally an inflammatory and oxidative-stress problem, and that extra oxygen calms inflammation, supports nerve tissue, and helps the body "reset." Supporters point to lab and clinical signals that HBOT can lower inflammatory cytokines like interleukin-6 and TNF, and reduce markers such as C-reactive protein in other conditions.

There is a real mechanistic story for HBOT reducing inflammation in general. The problem is the leap from "oxygen can modulate inflammation in some diseases" to "therefore it treats a contested mold syndrome." That leap has not been tested in any controlled way.

A second wrinkle: most mold clinics offer "mild HBOT" at 1.3 ATA (atmospheres absolute), not the 2.0 to 2.4 ATA used in hospital-grade protocols. Mild HBOT raises plasma oxygen far less than medical HBOT. Even if oxygen helped, the dose used in most wellness-clinic mold protocols is the weakest form. To understand why that distinction is contentious, see our breakdown of mild HBOT vs medical HBOT and why 1.3 ATA is controversial and our HBOT pressure guide on 1.3 vs 2.0 vs 2.4 ATA.

There is also a logical gap worth naming. The mold-toxicity story says the problem is mycotoxins lingering in your body. But HBOT does not bind, neutralize, or remove mycotoxins — it raises tissue oxygen. So even on the proponents' own terms, oxygen would not "detox" a stored toxin; at most it might dampen downstream inflammation. The phrase "HBOT detoxes mold," which appears on many clinic pages, describes a mechanism that does not match how the chamber works. Honest advocates frame HBOT as an anti-inflammatory support, not a detoxifier, and even that framing is unproven for this specific condition.

What the Direct Evidence Actually Shows

Here is the core of it. When you search the published literature for HBOT used specifically for CIRS or mold illness, you find essentially one study: a 2025 case report in Frontiers in Immunology by Coletti Giesler.

The report describes a single 60-year-old woman with a history of prolonged mold exposure in a water-damaged building. She underwent 40 sessions of low-pressure HBOT at 1.3 ATA with 24% oxygen over 10 weeks. The author reports that all 22 of her tracked symptoms resolved, her VCS score rose from 68% to 93%, and several CIRS biomarkers shifted in the expected direction — MMP-9 fell from 920 to 354 ng/mL, C4a fell from roughly 1,949 to 611 ng/mL, C3a dropped, and MSH rose.

Those numbers sound dramatic. But a case report is the weakest tier of clinical evidence. The author herself is explicit about why: it is a single-patient observational study with no control group, no blinding, and no long-term follow-up. As she writes, "the absence of a control group precludes definitive causal conclusions," and "larger-scale, controlled trials are needed to validate these findings." In plain terms: one person got better while doing many things, and we cannot know whether HBOT was the cause, a placebo effect, regression to the mean, or simply leaving the moldy environment.

Now widen the lens. A 2024 systematic review in Annals of Medicine and Surgery looked at the evidence for CIRS treatments overall. It examined 13 articles and concluded that the only treatment with documented clinical efficacy was the Shoemaker Protocol (medications and binders, not oxygen). HBOT does not appear anywhere in that review. So even within the literature produced by CIRS proponents, hyperbaric oxygen is not part of the validated protocol.

Evidence Grading Table

How the Evidence Tiers Compare

The takeaway: the entire published case for HBOT in mold illness rests on one patient. That is not a foundation for a $6,000 treatment package.

Why One Patient Getting Better Proves So Little

It is tempting to look at a 60-year-old woman whose 22 symptoms vanished and conclude the oxygen did it. Scientists resist that conclusion for concrete reasons, and they are worth spelling out so you can apply them yourself.

First, confounding. Over those 10 weeks, the patient almost certainly did more than sit in a chamber. People pursuing CIRS treatment typically also leave the moldy building, change their diet, start supplements or binders, reduce stress, and rest more. Any one of those — especially removing the exposure — could explain improvement. With everything changing at once, you cannot credit oxygen specifically.

Second, the natural course of illness. Chronic fatigue and brain-fog conditions wax and wane on their own. People tend to seek treatment when they feel worst, and they often improve afterward simply because they were at a low point — a statistical pattern called regression to the mean. A case report captures one slice of that curve and cannot distinguish a treatment effect from a natural rebound.

Third, placebo and expectation. Subjective symptoms like fatigue, mood, and cognition are strongly influenced by belief and ritual. Forty trips to a clinic, attention from staff, and a strong expectation of recovery can move symptom scores substantially even with an inert treatment. Even the VCS eye test, while objective-looking, can shift with practice, effort, and attention.

Fourth, publication and reporting bias. The patients who improve get written up; the ones who spend thousands and feel no different rarely make it into a journal. One published success tells you nothing about how many quiet failures sit behind it.

None of this means the patient is lying or that HBOT did nothing. It means a single uncontrolled story cannot tell us which explanation is true. That is precisely why a case report sits near the bottom of the evidence ladder.

What a Convincing Trial Would Look Like

To actually answer whether HBOT helps CIRS, you would need a randomized, sham-controlled trial: dozens of patients with the same diagnosis, randomly assigned to real HBOT or a convincing sham (a chamber that pressurizes slightly without therapeutic oxygen), with neither patients nor assessors knowing which is which. You would track validated symptom scales and predefined biomarkers over months, with follow-up to see if any benefit lasts. No such trial exists for HBOT in mold illness. Until one is run and replicated, anyone claiming HBOT "works" for mold toxicity is reaching far beyond the data.

Comparing HBOT to the Alternatives

If you believe you are sick from a water-damaged building, what does the evidence actually point toward?

Removing the exposure comes first. Across the mainstream and CIRS literatures alike, getting out of the moldy environment and remediating the moisture problem is the one universally agreed step. The CDC and EPA both center their guidance on fixing dampness, not on chamber-based treatments.

For diagnosed mold allergy, standard allergy care — antihistamines, nasal steroids, and sometimes immunotherapy — has real evidence behind it. This is the part of "mold illness" that conventional medicine treats confidently.

Within the CIRS framework specifically, the Shoemaker Protocol (binders like cholestyramine, plus a sequenced series of steps) is the only approach the 2024 review found to have documented efficacy, though that evidence is still low-tier and produced largely by the framework's own proponents.

HBOT sits outside all of this. It is neither a mainstream mold treatment nor a validated part of the CIRS protocol. It is an add-on being marketed on the strength of a single case report and general anti-inflammatory reasoning. If you are weighing oxygen against other wellness modalities, our comparison of HBOT vs ozone, EWOT, and EBOO covers how these alternative "detox" therapies stack up on evidence.

A useful sanity check is to compare the evidence behind HBOT's accepted uses with the evidence behind the mold claim. For diabetic foot ulcers, late radiation injury, and carbon monoxide poisoning, HBOT rests on randomized trials and decades of clinical use, which is why insurers cover it. For mold toxicity, the base is a single n=1 report. Same machine, wildly different evidence. When a clinic offers you HBOT for both a healing wound and "mold detox," it is selling one service backed by very different levels of proof — and only one of those uses would survive scrutiny.

It also helps to ask what you are actually buying. The realistic best case for HBOT here is a modest, temporary anti-inflammatory effect layered on top of the things that genuinely move the needle: leaving the moldy space and treating any real allergy. If those steps are skipped, no amount of chamber time addresses the cause. Spending money on oxygen while still living in a water-damaged home is treating a symptom while feeding the source.

Safety, Cost, and Realistic Expectations

HBOT is generally safe when run by trained staff in a proper chamber. The most common issues are ear and sinus barotrauma from pressure changes, temporary nearsightedness with long courses, claustrophobia, and rare oxygen toxicity. Mild HBOT at 1.3 ATA carries even lower physical risk simply because the pressure is gentler.

The bigger risks in the mold context are not physical — they are financial and diagnostic. A 40-session protocol like the one in the case report can run several thousand dollars out of pocket, since no insurer covers HBOT for mold toxicity or CIRS (these are not FDA-cleared indications). There is also the risk of chasing an unvalidated diagnosis and spending months on chambers and supplements while the real driver — a moldy home or an untreated allergy — goes unaddressed.

Set expectations honestly. It is possible some people feel better after HBOT for these symptoms. It is also possible that improvement reflects placebo, the natural ups and downs of chronic illness, or the fact that people often start HBOT right after leaving a bad environment. Without a control group, those explanations cannot be separated from a true treatment effect.

Who Might Reasonably Consider It — and Who Should Be Cautious

This is not medical advice, but here is a sober framing.

If you are drawn to HBOT for mold symptoms, the responsible path is to first confirm whether you have a treatable mold allergy with an allergist, remediate your environment, and rule out other causes of fatigue and brain fog. Treat HBOT as an unproven, self-funded experiment — not a cure — and only with a clinic that is transparent about the thin evidence.

Be especially cautious with any clinic that guarantees results, leans on urine mycotoxin tests to "diagnose" you, bundles HBOT with expensive supplement protocols, or claims oxygen "detoxes mold" from your body. Those are marketing claims, not findings. For more on spotting overreach, see our guide to HBOT clinic red flags and signs of unsafe practice, and for the broader pattern of overstated claims, our roundup of HBOT myths debunked.

Frequently Asked Questions

Does HBOT cure mold toxicity or CIRS?

No. There is no evidence that HBOT cures mold toxicity or CIRS. The only published study using HBOT for CIRS is a single-patient case report from 2025, which by design cannot prove cause and effect. The author explicitly states that controlled trials are needed before any conclusions can be drawn.

Is "mold toxicity" even a recognized medical diagnosis?

It is contested. Mold allergy is well accepted, but the broader claim that inhaled mycotoxins cause a systemic "toxicity" illness is rejected by bodies like the American College of Medical Toxicology, which states the evidence does not support significant toxic health effects from inhaled indoor mycotoxins. CIRS does not have universally accepted diagnostic criteria.

Why do some clinics use 1.3 ATA "mild" HBOT for mold?

Mild HBOT at 1.3 ATA is cheaper to run and lower-risk, and it is what most wellness clinics own. But it delivers far less oxygen than hospital-grade 2.0 to 2.4 ATA protocols. Even if oxygen helped with mold symptoms — which is unproven — the mild dose used in most mold protocols is the weakest version of the therapy.

Will insurance pay for HBOT to treat mold illness?

No. Mold toxicity and CIRS are not FDA-cleared HBOT indications, so insurers do not cover HBOT for them. Expect to pay fully out of pocket, often several thousand dollars for a multi-session course, with no guarantee of benefit.

If I feel better after HBOT for mold, doesn't that prove it worked?

Not necessarily. Feeling better is real and welcome, but it does not establish that HBOT was the cause. People often start HBOT right after leaving a moldy environment, while also taking supplements and changing their routine, and chronic symptoms naturally fluctuate. Placebo effects are strong. Only a controlled trial can separate a true HBOT effect from these other explanations, and that trial does not yet exist.

This article is for general education only and is not medical advice. Talk to a qualified physician — ideally an allergist or medical toxicologist — before starting any treatment for suspected mold-related illness.

Sources

• HBOT for CIRS case report (Frontiers in Immunology, 2025) — PubMed
• Full text of the 2025 HBOT-CIRS case report (PMC)
• CIRS treatment efficacy review (Annals of Medicine and Surgery, 2024) — PMC
• ACMT 2025 guidance on mold exposure and mycotoxin myths
• National Academies — Damp Indoor Spaces and Health (2004)
• CDC — Mold and your health
• EPA — Mold and moisture guidance
• PubMed search: hyperbaric oxygen chronic inflammatory response syndrome
• PubMed search: mold mycotoxin water-damaged building illness